阿尔茨海默氏症病理对与任务相关的大脑网络重新配置在衰老中的影响
Kaitlin E Cassady1,2, Xi Chen3,2, Jenna N Adams2
1Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720 kcassady@berkeley.edu.
概括
老年人与年轻人相比,在休息和记忆任务之间,大脑网络组织不那么一致. 功能连接的这种不稳定性与阿尔茨海默病的病理学,特别是,以及较差的记忆性能有关.
科学领域:
- 神经科学是一个神经科学.
- 认知老龄化 认知老龄化
- 神经退行性疾病 神经退行性疾病
背景情况:
- 大脑网络组织在年轻人的休息和任务状态之间通常是稳定的.
- 老化和神经退行性疾病,如阿尔茨海默氏症 (AD) 导致大脑网络的广泛变化.
- 老龄化和AD病理对休息和任务状态之间大脑网络功能的一致性的影响尚不清楚.
研究的目的:
- 研究休息和记忆任务之间的功能连接 (FC) 稳定性与年龄相关的差异.
- 探索老年人的AD病理 (粉样β和tau) 和FC稳定性之间的关系.
- 为了确定FC稳定性是否影响老年人的认知表现.
主要方法:
- 功能磁共振成像 (fMRI) 用于评估休息期间的FC和年轻人和老年人的物体场景记忆歧视任务.
- 应用了情节性记忆网络 (EMN) 分片来分析相关大脑区域内的FC.
- 用正子发射断层扫描 (PET) 来量化老年人中的粉样β (Aβ) 和tau水平.
主要成果:
- 与年轻人相比,老年人表现出休息和任务状态之间的相关性减少 (较低的FC相似性).
- 在EMN地区较低的FC相似性与老年人中较高的tau水平有关.
- 减少FC相似性与记忆任务期间对象试验的表现较差相关.
结论:
- 衰老与休息和记忆任务之间的功能大脑网络稳定性下降有关.
- 阿尔茨海默病的病理学,特别是,与与记忆相关的大脑区域的网络稳定性降低有关.
- 休息和任务状态之间更大的功能连接相似性可能支持老年人更好的记忆性能.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.4K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
